PEDIATRIC GROUP SPECIALISTS, LTD.

ARS Pharmaceuticals Reports Strong Q3 2025 Growth for Needle-Free Epinephrine Nasal Spray neffy

- ARS Pharmaceuticals achieved $32.5 million in Q3 2025 revenue, with $31.3 million from neffy U.S. sales, demonstrating continued commercial momentum for the first FDA-approved needle-free epinephrine treatment. - The company's direct-to-consumer campaign significantly boosted consumer awareness from 20% to 56% by September 2025, while over 18,000 healthcare providers have now prescribed neffy. - Real-world evidence from 680 patients showed approximately 90% effectiveness with a single neffy dose for anaphylaxis treatment, matching historical epinephrine injection outcomes. - Global expansion accelerated with neffy approvals in Japan and EUR neffy launches in Germany and the United Kingdom, establishing an international footprint for the needle-free epinephrine technology.